Compare Oracle Corporation (ORCL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs TG Therapeutics Inc — how do they compare? Oracle Corporation trades at $126.25 (market cap $365.96B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Oracle Corporation is far larger — about 44.3× TG Therapeutics Inc's market cap, and Oracle Corporation pays a 1.57% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ORCL | TGTX | |
|---|---|---|
Market Cap | $365.96B | $8.26B |
Sector | Technology | Health |
52-Week High | $328.33 | $59.06 |
52-Week Low | $121.37 | $26.39 |
Enterprise Value | $495.21B | $8.50B |
Dividend Yield | 1.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) is trading at $121.37, down 4.04% today, reflecting recent market volatility. The stock shows strong fundamentals with consistent earnings beats (Q3 2025-Q1 2026) and robust profitability metrics including 65.82% gross margin and 58.56% ROE. Technical indicators are mixed with a bearish moving average signal but bullish RSI readings. Recent news highlights Oracle's AI infrastructure expansion and partnership with OpenAI, driving investor interest despite concerns about capital requirements.
Oracle presents a compelling investment case with strong analyst support (65% buy ratings) and a $253.30 consensus price target representing significant upside. Key opportunities include AI-driven growth and cloud expansion, while risks involve high debt levels ($92.6B total liabilities) and competitive pressures in enterprise software. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
